Compare ROCK & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROCK | WVE |
|---|---|---|
| Founded | 1972 | 2012 |
| Country | United States | Singapore |
| Employees | 2221 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1996 | 2015 |
| Metric | ROCK | WVE |
|---|---|---|
| Price | $41.80 | $6.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $29.81 |
| AVG Volume (30 Days) | 324.2K | ★ 3.1M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,135,501,000.00 | $3,704,000.00 |
| Revenue This Year | $41.26 | N/A |
| Revenue Next Year | $20.14 | $85.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $33.56 | $5.02 |
| 52 Week High | $75.08 | $21.73 |
| Indicator | ROCK | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 59.33 | 46.80 |
| Support Level | $37.77 | $6.02 |
| Resistance Level | $42.73 | $7.65 |
| Average True Range (ATR) | 1.76 | 0.33 |
| MACD | 0.42 | 0.08 |
| Stochastic Oscillator | 78.04 | 61.84 |
Gibraltar Industries Inc manufactures and provides products and services for the Renewable energy, Residential, Agtech, and Infrastructure markets. The Renewable Segment is engaged in designing, engineering, manufacturing, and installing solar racking and electrical balance systems. Agtech Segment provides growing and processing solutions including the designing, engineering, manufacturing, full-scope construction, maintenance, and support of greenhouses and indoor growing operations, and botanical extraction systems. It derives key revenue from the Residential segment which offers roof and foundation ventilation products, single point and centralized mail systems electronic package solutions, and Retractable awnings and gutter guards, among other products.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.